Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Targeting a Weak Link in Pediatric Brain Cancer
Disease Discoveries

Targeting a Weak Link in Pediatric Brain Cancer

By Will DossAug 13, 2019
Share
Facebook Twitter Email
Xiao-Nan Li, MD, PhD, professor of Pediatrics in the Division of Hematology, Oncology, and Stem Cell Transplantation at Ann & Robert H. Lurie Children’s Hospital of Chicago and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was co-author of the study that discovered a weakness in a deadly pediatric brain cancer.

A group of scientists have discovered a weak link in the mutational cascade that drives a particularly deadly form of pediatric brain tumors, which may inspire future treatments, according to a study published in Cancer Cell.

Inhibiting protein interactions at one crucial step killed tumor cells, representing a promising therapeutic approach, according to Xiao-Nan Li, MD, PhD, professor of Pediatrics in the Division of Hematology, Oncology, and Stem Cell Transplantation at Ann & Robert H. Lurie Children’s Hospital of Chicago and co-author of the study.

Embryonal tumors with multilayered rosettes (ETMR) are brain tumors with a characteristic “wheel and spoke” arrangement of cells surrounding a central core. Occurring mostly in children under two, the overall survival rates are between 10 and 20 percent, according to the study.

The primary mutation that drives these tumors is an aberrant overactivation of the C19MC microRNA cluster, a group of 46 genes that curb gene expression. Normally, this cluster helps prevent cancer by preventing overactive cell growth, in addition to other functions. But, in ETMR, this gene cluster is fused to a gene promoter, and triggers a mutational cascade that causes a proliferation of primitive neural cells that eventually form tumors.

In the current study, scientists analyzed 80 tumor samples using transcription and epigenetic profiling, finding that the majority of tumors exhibited C19MC amplification. Few other mutations were this prevalent amongst the samples, underscoring the strength and singular ability of this mutation to cause ETMR.

Looking downstream, the investigators determined that interactions between C19MC and gene promoters created “super-enhancers,” short regions of DNA that increase the likelihood of transcribing a certain gene. While these super-enhancers can cause cancer by contributing to rapid cell growth, they also have consistent weaknesses that can be targeted by drugs, according to the study authors.

One emerging class of therapeutics are bromodomain inhibitors, a small molecule that shuts down super-enhancers by binding to them and preventing them from aiding transcription.

When the scientists applied a bromodomain inhibitor in ETMR cells, the cells either stopped growing or died.

While these tumors have been known to be difficult to treat because of their ability to hijack normal cell processes and proliferate nearly indefinitely, their apparently singular etiology may create a weakness that can be exploited. Future studies should examine this bromodomain inhibitor as a potential therapy, according to Li, whose lab created a novel panel of ETMR models that should serve as an important resource for future drug testing.

Li is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Stanley Manne Children’s Research Institute at Lurie Children’s. His lab created a novel panel of ETMR models through direct implantation of surgical specimen of pediatric ETMR tumors into the brains of immunodeficient mice.

This project was funded by a Canadian Institutes of Health Research (CIHR) grant no. 137011 and b.r.a.i.n. Child grant.

Cancer Genetics Pediatrics Research
Share. Facebook Twitter Email

Related Posts

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Comments are closed.

Latest News

Humans are Not Just Big Mice: Identifying Science’s Muscle-Scaling Problem

Mar 20, 2023

AOA Honors New Members

Mar 20, 2023

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
_5NM1245
230204_SERIO_MANDELL_Feinberg_Formal_0928
_5NM1715
_5NM0526
_5NM1026 (1)
_5NM1906
_5NM2173
230204_SERIO_MANDELL_Feinberg_Formal_0896
230204_SERIO_MANDELL_Feinberg_Formal_1113
230204_SERIO_MANDELL_Feinberg_Formal_1868
230204_SERIO_MANDELL_Feinberg_Formal_1237
230204_SERIO_MANDELL_Feinberg_Formal_1172

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.